ArticleDrug design, development and therapy2009

Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.

Thomas Scior et al.PubMed ↗Full text ↗

No numbers read from the abstract.